文献速递关节外科创伤骨科

糖尿病疾病严重程度与肩关节置换术后深部感染或翻修风险无关

Diabetes Disease Severity Was Not Associated with Risk of Deep Infection or Revision After Shoulder Arthroplasty.
PubMed 文献 · Clin Orthop Relat Res · 2019-01-01

基于Kaiser Permanente肩关节置换登记(2005-2015)的回顾性队列研究,纳入8819例初次肩关节置换患者,评估糖尿病状态及严重程度(HbA1c、aDCSI)与深部感染、全因翻修及90天再入院的关系。结果显示,在择期肩关节置换中,血糖控制不佳的糖尿病患者90天再入院风险较高(OR 1.5),aDCSI严重糖尿病在择期和创伤患者中均与90天再入院风险升高相关(OR分别为1.6和1.8);但糖尿病严重程度与深部感染或翻修风险无关,HbA1c和aDCSI对不良事件的区分能力均较差。

要点

  • 择期肩关节置换中,血糖控制不佳(HbA1c≥7.0%)的糖尿病患者90天再入院风险升高(OR 1.5,95%CI 1.0-2.1,p=0.032)。
  • aDCSI严重糖尿病(评分≥3)在择期和创伤肩关节置换中均与90天再入院风险升高相关(OR分别为1.6和1.8)。
  • 糖尿病状态及严重程度与深部感染或全因翻修风险无关,HbA1c和aDCSI对不良事件的区分能力均较差。

核心结论

  • 在所评估的较长时期结局中,更严重的糖尿病仅与肩关节置换术后90天再入院增加相关,使用aDCSI识别糖尿病严重程度时关联更强。
  • HbA1c的任意切点可能不是确定术后结局风险的最佳方法。
  • 未来研究应识别和验证如aDCSI等能更好识别术后结局高风险患者的指标,并探究通过靶向干预改善这些指标能否改善结局。

研究设计与样本

  • 回顾性登记队列研究,使用Kaiser Permanente肩关节置换登记(2005-2015)数据。
  • 纳入初次肩关节置换患者,分为有糖尿病和无糖尿病;糖尿病患者进一步按HbA1c(良好控制<7.0%,控制不佳≥7.0%)和aDCSI(轻度0-2分,严重≥3分)评估严重程度。
  • 采用Cox回归评估深部感染和翻修风险,条件logistic回归评估90天再入院,术后1年HbA1c作为时变变量评估翻修风险,所有模型调整协变量并按择期与创伤分层。
  • 研究样本共8819例,其中择期肩关节置换7353例,创伤肩关节置换1466例;择期患者中1430例(19%)有糖尿病,创伤患者中444例(30%)有糖尿病。

主要发现

  • 择期肩关节置换中,血糖控制不佳的糖尿病患者较无糖尿病患者90天再入院可能性更高(OR 1.5,95%CI 1.0-2.1,p=0.032);创伤肩关节置换患者中未发现关联。
  • 术后HbA1c与翻修风险之间未发现关联。
  • 受试者工作特征曲线分析提示术前HbA1c区分不良事件的能力较差。
  • 使用aDCSI时,严重糖尿病患者在择期和创伤肩关节置换中较无糖尿病患者90天再入院可能性更高(OR 1.6,95%CI 1.2-2.2,p=0.001;OR 1.8,95%CI 1.2-2.7,p=0.005)。
  • 与HbA1c类似,aDCSI区分不良事件的能力也较差。

关键数值与推荐

  • 血糖控制良好定义为术前HbA1c<7.0%,控制不佳定义为HbA1c≥7.0%。
  • aDCSI轻度定义为评分0-2分,严重定义为评分≥3分。
  • 择期肩关节置换中血糖控制不佳的糖尿病患者90天再入院OR 1.5(95%CI 1.0-2.1,p=0.032)。
  • 严重糖尿病患者择期肩关节置换90天再入院OR 1.6(95%CI 1.2-2.2,p=0.001),创伤肩关节置换OR 1.8(95%CI 1.2-2.7,p=0.005)。

临床怎么用

  • 作者认为,HbA1c的任意切点可能不是确定术后结局风险的最佳方法。
  • 作者建议未来工作应识别和验证如aDCSI等能更好识别术后结局高风险患者的指标,并探究通过靶向干预改善这些指标能否改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior studies have identified diabetes and disease severity (defined using hemoglobin A1c [HbA1c]) as potential risk factors for complications after shoulder arthroplasty. Evaluations of diabetes status and risk of adverse outcomes beyond the 30-day window either are limited or have not accounted for disease severity. Further, measures of diabetes severity other than HbA1c have yet to be investigated in a shoulder arthroplasty population. QUESTIONS/PURPOSES: (1) Are diabetes status and glycemic control associated with adverse events, including deep infection, all-cause revision, and 90-day readmission after shoulder arthroplasty? (2) Is postoperative HbA1c associated with revision risk? (3) Is there a threshold of preoperative HbA1c that best identifies patients with diabetes who are at higher risk of 3-year deep infection, 1-year all-cause revision, or 90-day readmission? (4) Can the Adapted Diabetes Complications Severity index (aDCSI) be used as an alternative measure of diabetes severity in evaluating the risk of deep infection, all-cause revision, and 90-day readmission and identification of patients with diabetes at higher risk for these events? (5) Is there a difference between elective and traumatic shoulder arthroplasty patients? METHODS: We conducted a retrospective registry-based cohort study using Kaiser Permanente's Shoulder Arthroplasty Registry (2005-2015). Primary shoulder arthroplasties were classified as patients with and without diabetes. Patients with diabetes were further evaluated using two disease severity measures (1) HbA1c, with good glycemic control classified as preoperative HbA1c < 7.0% and poor control defined as HbA1c ≥ 7.0%; and (2) aDCSI, classified as mild (score of 0-2) or severe (score ≥ 3) diabetes. Cox regression was used to evaluate the risk of deep infection and revision according to diabetes status and disease severity; conditional logistic regression was used for 90-day readmission. Time-dependent 1-year postoperative HbA1c was used to evaluate revision risk in Cox regression. All models were adjusted for covariates and stratified by elective versus trauma shoulder arthroplasty. Receiver operating characteristic curves were generated for HbA1c and aDCSI to determine whether a threshold exists to identify patients at higher risk of deep infection, all-cause revision, or 90-day readmission. The study sample consisted of 8819 patients; 7353 underwent elective shoulder arthroplasty and 1466 underwent shoulder arthroplasty due to trauma. For elective shoulder arthroplasty, 1430 patients (19%) had diabetes, and among the patients who underwent arthroplasty due to trauma, 444 (30%) had diabetes. RESULTS: Patients with diabetes who underwent elective shoulder arthroplasty and had poor glycemic control had a higher likelihood of 90-day readmission compared with patients without diabetes (OR, 1.5; 95% CI, 1.0-2.1; p = 0.032). No association was found for patients with diabetes who underwent shoulder arthroplasty due to trauma. No association was found between postoperative HbA1c and revision risk. Receiver operating characteristic curve analysis suggested preoperative HbA1c performed poorly at differentiating adverse events. When using aDCSI, patients with severe diabetes who underwent both elective and traumatic shoulder arthroplasty had a higher likelihood of 90-day readmission compared with patients without diabetes (OR, 1.6; 95% CI, 1.2-2.2; p = 0.001 and OR, 1.8; 95% CI, 1.2-2.7; p = 0.005, respectively). Similar to HbA1c, the aDCSI was a poor classifier in differentiating adverse events. CONCLUSIONS: Of the longer-term outcomes evaluated, more-severe diabetes was only found to be associated with an increase in 90-day readmissions after shoulder arthroplasty; a stronger association was found when using the aDCSI in identifying diabetes severity. Arbitrary cutoffs in HbA1c may not be the best method for determining risk of postoperative outcomes. Future work investigating perioperative diabetes management should work to identify and validate measures, such as the aDCSI, that better identify patients at higher risk for postoperative outcomes and, more importantly, whether outcomes can be improved by modifying these measures with targeted interventions. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. McElvany MD, Chan PH, Prentice HA, et al. Diabetes Disease Severity Was Not Associated with Risk of Deep Infection or Revision After Shoulder Arthroplasty. Clin Orthop Relat Res. 2019. PMID: 31136435. doi:10.1097/CORR.0000000000000642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。